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Key Points 
• Edible cannabis products, cannabis extracts and cannabis topicals have 
unique health and safety risks that are not inherent to dried cannabis. 
• High-potency cannabis extracts increase the risk of over-intoxication more 
than dried cannabis. Although limited, the available evidence indicates that 
frequent use of these products is associated with problematic cannabis use, 
cannabis use disorder and mental health disorders.
• Edible cannabis products can increase the risk of over-consumption and 
subsequent over-intoxication and impairment. Because when unpackaged 
they look like ordinary food and beverage products, edible cannabis products 
also increase the risk of unintentional ingestion, especially by children. 
• Research on cannabis topicals, including the use of topical and transdermal 
cannabidiol products, is limited. There is, however, growing interest among 
dermatologists and consumers in these cannabis products.
• The health impacts associated with long-term use of edible cannabis 
products, cannabis extracts and cannabis topicals are not known. 
• Public education efforts will play an important role in mitigating the harms 
associated with new cannabis products.
Background
On October 17, 2019, Canada legalized the production and sale of several new cannabis 
products, including edible cannabis products (or “edibles”), cannabis extracts and 
cannabis topicals. Legalization will increase accessibility to a wide variety of products 
and methods of consumption for individuals who choose to use cannabis. While 
these products might look, smell and taste different from dried cannabis, “cannabis is 
cannabis.” In other words, most of the short- and long-term health impacts associated 
with the use of dried cannabis also apply to edible cannabis products, cannabis extracts 
and, to a lesser extent, cannabis topicals. However, these new cannabis products also 
are accompanied by several additional health and safety risks that are not inherent to 
dried cannabis. 
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This is the seventh in a series of 
reports that reviews the effects of 
cannabis use on various aspects of 
human functioning and development. 
Other reports in this series address 
the link between regular cannabis use 
and mental health, regular cannabis 
use and cognitive functioning, maternal 
cannabis use during pregnancy, 
cannabis use and driving, respiratory 
and cardiovascular effects of smoking 
cannabis, and the medical use of 
cannabis and cannabinoids. This series 
is intended for a broad audience, 
including health professionals, policy 
makers and researchers.
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2This report reviews the available, albeit limited, scientific 
evidence on edible cannabis products, cannabis extracts 
and cannabis topicals, with a particular focus on what 
distinguishes these new products from dried cannabis. It 
provides an overview of current and anticipated cannabis 
products based on information available in Canada and 
the United States. The range of products available will likely 
continue to grow as the market evolves and updates to 
this report will be made accordingly. The report will assist 
healthcare practitioners, policy makers and public heath 
organizations in developing public education resources 
and harm reduction strategies related to the use of edible 
cannabis products, cannabis extracts and cannabis 
topicals. It also draws attention to the evidence gaps in 
this relatively new area of research. 
Cannabis Extracts
A cannabis extract can, in essence, be any product that 
contains cannabinoids that have been extracted from 
the cannabis plant. Cannabis extracts vary greatly in their 
appearance and consistency, taste and smell, and in their 
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What is dabbing?
Dabbing is a relatively new way to vape 
concentrates. Dabbing is a method of vaporizing 
solid concentrates. A small piece or “dab” of 
concentrate is placed against a hot surface, such 
as the nail in a dab rig or coil in a wax pen (two 
specialized accessories used for dabbing). Once 
the concentrate has vaporized, all of the vapor is 
usually inhaled in a single breath. 
Dabbing and maintaining a dab rig can be 
complicated and is not recommended for 
beginners. However, data from the United States 
shows that dabbing is becoming increasingly 
popular, especially among younger populations 
(Stogner & Miller, 2015). This trend is concerning 
because dabbing increases the risk of over-
intoxication (Pierre, Gandal, & Son, 2016) and 
cardiovascular toxicity (Rickner, Cao, Kleinschmidt, 
& Fleming, 2017). Regular dabbing also increases 
the risk of cannabis-related problems, including 
tolerance and dependence (Meier, 2017; Loflin & 
Earleywine, 2014). In a national online survey in the 
United States, individuals who used dabs regularly 
indicated that they were more worried about their 
use of these cannabis products relative to those 
who tried dabs but did not use them regularly 
(Sagar, Lambros, Dahlgren, Smith, & Gruber, 2018). 
What are cannabinoids and terpenes?
Cannabinoids are the chemical compounds 
found in the cannabis plant, some of which can 
affect the mind and body when consumed. THC 
(Δ9-tetrahydrocannabinol) is the best known 
cannabinoid. This cannabinoid has intoxicating and 
impairing effects, with high doses leading to severe 
anxiety, panic, heart palpitations and symptoms of 
psychosis (e.g., paranoia). Research is ongoing to 
determine whether THC has medical benefits for 
certain health conditions. CBD (cannabidiol) ) is a 
cannabinoid that has gained increased attention for 
its therapeutic potential, although more research is 
needed to confirm its usefulness and effectiveness 
for medical purposes. CBD does not produce the 
characteristic high that is attributed to THC, but it 
appears to have sedative properties. The cannabis 
plant has at least one hundred more cannabinoids, 
about which little is known. Among other 
constituents, the cannabis plant also has terpenes, 
which are substances that contribute to the smell 
and taste of cannabis. It has been suggested that 
terpenes modulate the effects of THC and CBD on 
the mind and body (referred to as the entourage 
effect), although this suggestion has yet to be 
extensively examined. . 
THC and CBD (and other lesser known cannabinoids) 
concentrations. The term “concentrate”1 has been applied 
to cannabis extracts that contain high concentrations 
(e.g., ~ 60%) of THC (Raber, Elzinga, & Kaplan, 2015). 
A recent study of the Washington State legal cannabis 
market found that cannabis concentrates are now averaging 
70% to 80% THC (Davenport, 2019). While it is possible to 
create concentrated CBD products (e.g. CBD oils), these are 
typically not referred to as concentrates. Cannabis extracts 
are commonly smoked or vaporized (“vaped”), alone or 
mixed with dried cannabis. They can also be ingested, alone 
or in capsule form, or administered sublingually (i.e., under 
the tongue). Dabbing is becoming an increasingly popular 
method of inhaling concentrates, particularly among youth 
(Stogner & Miller, 2015). To get a sense of the diversity 
of cannabis extracts being used and produced, Table 1 
provides a brief description of some of the more common 
products.
1 Canadian Cannabis Regulations state that a “cannabis concentrate means a substance that has a concentration of greater than 3% [weight per 
weight] of THC, taking into account the potential to convert THCA into THC” (Government of Canada, 2018).
3Product Description Method of Use Average Levels of 
THC and CBD2
Hash
Hash or hashish is the oldest and best-known type of 
cannabis extract. It is a light to dark brown substance 
composed of compressed or purified trichomes, which 
are the stalked resin glands that contain most of the 
cannabinoids present in the cannabis plant. Hash that has 
been pressed is usually solid, whereas water-purified hash 
develops a paste-like consistency and is often called “bubble 
melt hash” or “bubble hash.”
- Smoked (either 
alone or mixed 
in with dried 
cannabis or 
tobacco)
- Vaped 
- Dabbed 
THC: 40–80% 
CBD: less than 5%
Kief
Kief refers to the collection of trichomes that accumulate 
when sifted from dried cannabis, often using a three-
chamber grinder.
- Smoked (either 
alone or mixed 
in with dried 
cannabis or 
tobacco)
THC: 40–50% CBD: 
less than 5%
Wax (crumble, budder)
Wax is a solvent-based (e.g., butane3) extract that is named 
after its appearance and consistency. Wax varies in level of 
THC depending on quality, but can contain well over 50% 
THC. Crumble is the drier and more crumbly form of wax, 
whereas budder contains a higher moisture content.
- Vaped 
- Dabbed 
THC: 26–70%
CBD: --
Shatter
Shatter is amber and glass-like in appearance and 
consistency. It is generally high in THC and low in CBD. 
Compression following the extraction process turns shatter 
into a substance called “cookie crumble” or “honeycomb.”
- Vaped 
- Dabbed 
THC: ~ 70%
CBD: --
Live Resin 
Live resin is made the same way as wax, but with fresh 
cannabis plant material that has been immediately frozen 
after harvest. This is the reason for the term “live.” This 
process gives live resin a “more intense and complex” 
smell and taste, so it is more expensive than typical wax 
and budder products. The moisture in this extract gives it a 
slightly different appearance from wax and budder.
- Vaped 
- Dabbed 
THC: 40–50%
CBD: --
Rosin
Rosin refers to cannabis extracts that were made using 
“rosin tech,” which is essentially the application of heat and 
compression to the resinous sap from cannabis plant matter, 
most often flower (or bud), kief or hash. This extraction 
method results in a sappy and translucent cannabis 
extract that is similar in appearance and composition to 
shatter. It is believed that rosin can reach comparable THC 
concentrations to that in solvent-based extracts, but this has 
yet to be scientifically tested.
- Vaped 
- Dabbed 
THC: ~ 70%
CBD: --
2 Canadian Cannabis Regulations state that a “cannabis concentrate means a substance that has a concentration of greater than 3% [weight per 
weight] of THC, taking into account the potential to convert THCA into THC” (Government of Canada, 2018).
3 Cannabis extracts using butane are often called butane hash oils (BHOs). BHOs appear to be common in the United States, particularly in illicit and 
unregulated markets (Al-Zouabi, Stogner, Miller, & Lane, 2018). It is currently unclear whether butane is a commonly used solvent on the Canadian 
illicit market or whether other solvents (e.g., CO2) and extraction processes (e.g., distillation) are being used. 
Table 1. Summary of cannabis extracts
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Prevalence and Reasons for Use 
Presently, there is no complete picture of the type and 
frequency of cannabis extracts being used by Canadians. 
However, several nationally representative surveys have 
begun to assess the prevalence of use of cannabis 
concentrates by Canadians. Data from the 2019 Canadian 
Cannabis Survey indicate that, among individuals who had 
used cannabis in the past 12 months, 23% said they had 
used hash or kief, 26% had used a cannabis oil cartridge or 
disposable vape pen and 17% had used a solid concentrate 
(shatter, budder, etc.) (Health Canada, 2019). The use of 
these cannabis products was more common among males 
and those aged 16 to 24 (Health Canada, 2019). Similarly, 
data from a large international survey showed that, among 
Canadians who reported using cannabis in the past 
12 months, 25.1% said they had used hash or kief, 22.2% 
had used a cannabis oil for ingestion, 20.9% had used a 
cannabis oil for vaping, 16.8% had used a concentrate 
and 6.6% had used a tincture (Goodman, Wadsworth, 
Leos-Toro, Hammond, & International Cannabis Policy 
Study Team, 2020). 
It is unclear how these patterns of use will change as new 
cannabis extracts become legally available in Canada. 
Research from the United States, particularly in states where 
these products are legal, might provide insight into what 
Canada can expect. A 2016 web-based survey of people 
living in the United States who use cannabis found that the 
use of cannabis concentrates was associated with greater 
odds of living in states with less restrictive recreational 
and medical cannabis policies (Daniulaityte et al., 2017). 
Consistent with the Canadian data, this study also found 
4
Product Description Method of Use Average Levels of THC and CBD1
Tinctures and Oil Sprays
Tinctures and oil sprays are products 
consisting of a cannabis extract, a 
carrier liquid, such as coconut-derived 
MCT (medium-chain triglycerides) 
oil, and sometimes terpenes. These 
products vary widely in their THC 
and CBD levels and reasons for 
use. Tinctures come in plastic or 
glass bottles with droppers and 
are administered under the tongue 
(sublingually). Oil sprays are similarly 
intended to be sprayed under the 
tongue. 
- Sublingual
- Ingested
High THC:
THC: 20–30 mg/ml
CBD: 0–1 mg/ml 
High CBD:
THC: 0.7–2 mg/ml
CBD: 15–55 mg/ml
Balanced: 
THC: 1–12.5 mg/ml 
CBD: 1–12.5 mg/ml
Softgels and Capsules 
Softgels and capsules are comprised 
of similar ingredients to that of 
tinctures and oil sprays: a cannabis 
extract, a carrier liquid (e.g., MCT) 
and, sometimes, terpenes. These 
products vary widely in their THC and 
CBD levels.
- Ingested High THC:
THC: 2.5–10 mg/capsule
CBD: 0–1 mg/capsule
Capsules on the illicit market appear to 
contain up to 100 mg of THC.
High CBD:
THC: O–1 mg/capsule
CBD: 9–25 mg/capsule
Balanced: 
THC: 2–3 mg/capsule
CBD: 2–3 mg/capsule
 Vape Cartridges and Disposable Pens
Vape cartridges and pens contain 
high concentrated cannabis extracts 
and varying terpene (flavour) profiles. 
High THC vape products are the most 
commonly sold. However, it appears 
that high CBD and “balanced” vape 
products are becoming increasingly 
available. 
- Vaped High THC:
THC: 70–95% 
CBD: 0–10% 
High CBD:
THC: 0–5%
CBD: 60–70%
Balanced: 
THC: 40–60%
CBD: 20–40%
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that the use of cannabis concentrates, especially daily use, 
was associated with being male, being younger and using 
dried cannabis daily, and lower perceived risks associated 
with use of these concentrates (Daniulaityte et al., 2017). 
In line with these findings, an online survey conducted on 
people living in California, Colorado, Nevada, Oregon and 
Washington state found that, relative to those who never or 
occasionally used concentrates, individuals who frequently 
used these products experienced more symptoms of 
cannabis use disorder and used higher-strength cannabis 
even when not using concentrates. Interestingly, these 
individuals did not differ in self-reported physical and mental 
health or life satisfaction (Cinnamon Bidwell, YorkWilliams, 
Mueller, Bryan, & Hutchison, 2018). 
In contrast to these later findings, more frequent use 
of butane hash oils was associated with higher levels of 
physical dependence, impaired control, cannabis-related 
academic or occupational problems, poor self-care and 
cannabis-related risk behaviour. After accounting for 
sociodemographic factors, age of onset of cannabis use, 
sensation seeking, overall frequency of cannabis use and 
frequency of other substance use, butane hash oil use was 
only associated with higher levels of physical dependence 
(Meier, 2017). In a large online survey conducted in over 
20 countries (181,870 people), frequent use of concentrates 
was associated with a lifetime diagnosis of depression, 
anxiety and a greater number of substances used 
(Chan et al., 2017). 
Collectively, these findings suggest that the use of 
concentrates is associated with problematic substance use 
and mental health disorders. However, it is unclear whether 
the use of high THC extracts and concentrates leads to 
diminished mental health and cannabis-related problems, 
whether these mental health outcomes predate the use of 
concentrates, or whether another factor accounts for both.
There has been little research investigating reasons why 
some individuals use cannabis extracts and concentrates 
over dried cannabis, or why they might prefer certain 
products over others. Qualities inherent to cannabis 
extracts and concentrates (e.g., cannabinoid profile) 
and the way in which they can be consumed, might 
predict preferences for particular products. For example, 
vaporizing or “vaping” is one of the more common ways of 
consuming cannabis extracts and concentrates. Because 
vaping is thought to minimize harmful effects to the lungs, 
this method of inhalation might become an increasingly 
popular way to consume cannabis, and one that facilitates 
the use of extracts and concentrates (e.g., vape pens) (e.g., 
Kowitt et al., 2019). However, as described in a recent brief 
from CCSA, Vaping Linked with Severe Lung Illnesses, 
vaping cannabis products has risks (Canadian Centre on 
Substance Use and Addiction, 2019).
Vaping does not produce the smell associated with 
smoking cannabis, making it a more discrete and versatile 
way of consuming it. An online survey conducted in the 
United States found that individuals were more likely to 
have vaped cannabis in locations other than a private 
residence, including in a motor vehicle, and more frequent 
vaping was associated with driving while impaired (Jones, 
Meier, & Pardini, 2018). These findings have implications for 
impaired driving and workplace health and safety. 
Reasons for the use of certain cannabis extracts and 
concentrates might also vary by the cannabinoid profile 
(e.g., THC:CBD ratio) of the product. Concentrates, which 
are high in THC, are more commonly used by individuals 
who are experienced with cannabis and who generally 
consume cannabis more regularly (Cinnamon Bidwell et al., 
2018; Daniulaityte et al., 2017). A recent online survey found 
that individuals who used concentrates said they did so for 
experimentation and out of curiosity (Sagar et al., 2018), 
but these products also appear to be more commonly used 
by individuals using cannabis for therapeutic purposes 
(Daniulaityte et al., 2017). However, 2019 data from the 
Canadian Cannabis Survey seems to show that the use 
of concentrates (e.g., shatter, budder) is less common 
among individuals using for medical purposes (13.1% said 
they used a cannabis concentrate or extract in the past 12 
months), relative to those using for non-medical reasons 
(17.3% said they used a cannabis concentrate or extract 
in the past 12 months) (Health Canada, 2019). It is worth 
mentioning, however, that the line between medical and 
non-medical cannabis use is becoming increasingly blurred 
(Morean & Lederman, 2019). 
CBD is steadily gaining a possibly premature reputation 
for having a variety of health and medical benefits. There 
is promising research supporting some benefits of CBD, 
THC and other cannabinoids for certain health conditions, 
including relief of chronic pain, anxiety and insomnia 
(Babson, Sottile, & Morabito, 2017; Bonaccorso, Ricciardi, 
Zangani, Chiappini, & Schifano, 2019; Lee, Bertoglio, 
Guimarães, & Stevenson, 2017; Lee, Grovey, Furnish, & 
Wallace, 2018; Jensen, Chen, Furnish, & Wallace, 2015; 
MacCallum & Russo, 2018). However, except for a few 
specific research programs (e.g., use of CBD for the 
treatment of seizures associated with rare forms of epilepsy 
in young children [Friedman, French, & Maccarrone, 
2019]), there is little high-quality research assessing the 
efficiency of CBD in treating any health condition and the 
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safety of long-term use of CBD is unknown. CBD can 
also facilitate or inhibit the actions of a number of different 
drugs, especially those metabolized by CYP450 enzymes 
(e.g., opioids, benzodiazepines and antidepressants), and 
research assessing potential drug interactions is generally 
lacking (Brown & Winterstein, 2019). Despite the lack of 
evidence, there is a considerable amount of interest in CBD 
among Canadians. Moreover, as indicated in the 2019 
Canadian Cannabis Survey, products higher in CBD and 
lower in THC are the most common types of products 
used among individuals for medical purposes, especially 
females. Parenthetically, only 33.5% of those reporting 
medical use had medical documentation for this purpose 
(Health Canada, 2019). 
Taken together, the available research suggests that reasons 
for using cannabis extracts and concentrates might vary by 
product type, method of use and context. A more in-depth 
understanding of these topics could be gained through 
the use of qualitative research methods, which should also 
encompass diverse groups of individuals, including those 
of varying age, sex, gender, culture and ethnicity. 
Health and Safety Risks
The health and safety risks associated with the use of 
cannabis extracts and concentrates have not been well 
characterized. The available evidence suggests that the 
risks vary depending on the type of product (including the 
ingredients in the product) and method of use and are 
proportional to the amount of THC in the product. Individuals 
who indicated they used a variety of high-strength cannabis 
product reported that they had experienced stronger 
negative effects and less positive effects when using butane 
hash oils relative to high-potency dried cannabis (Chan et 
al., 2017). Similarly, a case series from the United States 
found that dabbing, an increasingly popular method of 
vaping concentrates, led to significant adverse health 
effects, including psychosis, neurotoxicity and cardiotoxicity 
(Alzghari, Fung, Rickner, Chacko, & Fleming, 2017). Although 
limited, this evidence suggests that concentrates, because 
of their high THC levels, carry with them an increased risk of 
over-intoxication, beyond that which is attributable to dried 
cannabis use (Allen et al., 2017). 
In the United States, as of January 21, 2020, 2,711 
individuals have been hospitalized or have died of lung 
injury associated with using e-cigarettes or vaping products 
(Centers for Disease Control and Prevention, 2020, Feb. 4). 
In Canada, as of January 28, 2020, 17 cases of lung illness 
associated with vaping but no deaths have been reported 
to the Public Health Agency of Canada (Government of 
Canada, 2020). An additive (or contaminant) called vitamin 
E acetate in illegal and unregulated cannabis vape liquids 
is currently suspected as the chemical responsible for the 
cases of lung injury. However, other chemicals cannot be 
ruled out at this time. In fact, vape oils, especially those 
on the illicit market, can contain an array of chemicals 
(e.g., flavourings, carrier liquids, particulates of the vape 
device or cartridge) that when heated and inhaled can be 
harmful to lung tissue. Research on the respiratory effects 
of repeated exposure to many of these chemicals has not 
been conducted. The injuries from vaping underscore the 
importance of being well informed of the health and safety 
risks associated with cannabis vaping products and all 
cannabis products before considering their use. An equally 
important message is for individuals to purchase cannabis 
products, including vape oils, from legal and regulated 
retailers and producers as products from these sources are 
strictly regulated and assessed for quality and the presence 
of contaminants. For a more comprehensive account of 
vaping-related lung illness, see Vaping Linked with Severe 
Lung Illnesses.
Edible cannabis products have received most of the attention 
around concerns of unintentional ingestion by children and 
pets. This concern also applies to cannabis extracts and 
concentrates. A 2017 systematic review found that the 
most common cannabis product ingested by children was 
a resin, followed by cookies and joints (Richards, Smith, & 
Moulin, 2017). Indeed, public education on proper labelling 
(e.g., amounts of THC, CBD and other ingredients), storage 
and disposal of all types of cannabis products will play an 
important role in mitigating the risk of unintentional ingestion. 
For a resource on how to safely store cannabis products, 
see CCSA’s How to Safely Store Your Cannabis. 
The health impacts associated with regular use (weekly 
or more frequent use for long periods of time) of cannabis 
extracts and concentrates are not known. It is likely that 
most of the health concerns that have been identified 
with regular use of dried cannabis, which are mostly 
attributed to THC, also apply to cannabis extracts and 
concentrates. Regular use of cannabis has been associated 
with difficulties in cognitive functioning (e.g., memory and 
concentration) (Scott et al., 2018) and an increased risk of 
developing certain mental illnesses, including psychosis and 
schizophrenia (Lowe, Sasiadek, Coles, & George, 2019). 
Regular use of cannabis during pregnancy has been related 
to increased risk of developmental disturbances (e.g., 
lower birth weight) in children of mothers who had smoked 
cannabis heavily (Corsi et al., 2019). Frequent exposure 
to cannabis smoke can lead to respiratory system harms, 
including bronchitis (Ribeiro & Ind, 2016). A comprehensive 
overview of the health impacts of cannabis use is provided 
in CCSA’s Clearing the Smoke on Cannabis series.
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A growing body of evidence suggests that the mental 
health impacts of cannabis use are not dependent only on 
frequency of use, but also on the amount or concentration of 
THC in the product. For example, in a study that examined 
the prevalence of first-episode psychosis across 11 sites 
in Europe and Brazil, daily cannabis use was associated 
with increased odds of psychotic disorder compared with 
those who do not use cannabis, increasing to nearly five 
times greater odds for daily use of high-potency types of 
cannabis. Statistical analyses indicated that if high-potency 
cannabis were no longer available, 12.2% of cases of 
first-episode psychosis could be prevented across the 
11 sites (Di Forti et al., 2019). Further, supporting the notion 
that higher potency cannabis products carry greater risks 
to mental health, a large online survey conducted in over 
20 countries found that frequent use of concentrates was 
associated with a lifetime diagnosis of depression, anxiety 
and a greater number of substances used (Chan et al., 
2017). As well, individuals who dabbed reported that this 
method of vaping concentrates led to higher tolerance 
and withdrawal (as defined by the participants) (Loflin & 
Earleywine, 2014). More frequent use of butane hash oils 
was associated with higher levels of physical dependence, 
even after controlling for sociodemographic factors, age of 
onset of cannabis use, sensation seeking, overall frequency 
of cannabis use and frequency of other substance use 
(Meier, 2017). Consistent with these findings, a recent 
study found that, after accounting for the concurrent 
use of multiple cannabis products, the use of cannabis 
concentrates was strongly predictive of a progression from 
experimentation to persistent use over a 12-month period 
(Barrington-Trimis et al., 2020). 
Collectively, the evidence suggests that the use of higher-
potency cannabis products, especially concentrates, 
is associated with mental illness and symptoms of 
dependence. The causal direction of these associations and 
whether the relationship between mental illness and regular 
use of concentrates is reciprocal remains to be determined.
Edible Cannabis Products
Edible cannabis products, popularly known as “edibles,” are 
food and beverage products that have been infused with a 
typically oil- or alcohol-based cannabis extract. Edibles can 
take many different forms, including chocolates, cookies, 
brownies, candies and various types of beverages (Barrus 
et al., 2016). Essentially, anything you can add a cannabis 
extract to can be considered an edible and making these 
products is a relatively easy process. The main step in the 
process is to ensure that the cannabis product (e.g., dried 
cannabis or extract) has been sufficiently “decarboxylated” 
prior to combining with food ingredients. Edible cannabis 
products vary considerably in their concentrations of THC 
and other cannabinoids, particularly in the illegal and 
unregulated markets. In Canada, the legal limit of THC 
per package of edible cannabis is 10 mg, although it is 
recommended that individuals who are new to cannabis 
start with no more than 2.5 mg of THC. 
Prevalence and Reasons for Use 
Data from the 2019 Canadian Cannabis Survey indicated 
that, among individuals who used cannabis in the past 
12 months, 44% said that they had eaten cannabis in 
food, which was an increase from 41% in 2018 and 34% in 
2017 (Health Canada, 2019). This survey further indicated 
that, while a greater percentage of males reported using 
dried flower, hash and concentrates or extracts, higher 
percentage of females reported using edible food products 
(48%) compared to males (42%). These data suggest that 
males prefer dried flower and concentrates, while females 
prefer edible cannabis products.
There has yet to be any published research exploring why 
Canadians consume edible cannabis. A qualitative study 
conducted in the United States indicated that individuals 
prefer edible cannabis to smoked cannabis because with 
no smoke there is no smell and no second-hand smoke. 
Participants in the study also liked the convenience, 
discreetness, longer-lasting highs and less-intense highs 
associated with edibles, and the perceived ability of these 
cannabis products to aid in relaxation and reduce anxiety 
more so than smoking cannabis. On the other hand, 
participants disliked the delayed effects, unexpected highs 
and the unpredictability of the high, and were concerned 
about the inconsistent distribution of cannabis in the 
products (Giombi, Kosa, Rains, & Cates, 2018). 
A study conducted in San Francisco examined gender 
differences in perceptions of edible cannabis among 15 to 
19 year olds. This study found that young men and women 
used edibles mainly to reduce the likelihood of getting 
7
What is decarboxylation?
Eating or drinking raw cannabis will not produce 
intoxicating or impairing effects because the 
main cannabinoid that produces these effects 
(THC) is in a different form. In the living cannabis 
plant, THC has a carboxyl group attached to it, 
making it tetrahydrocannabinolic acid or THCA. 
Decarboxylation is the process of removing the 
carboxyl group, which is achieved through heat and 
time (Casiraghi et al., 2018). Smoking and vaping 
are the fastest ways to decarboxylate cannabinoids, 
although drying or curing raw cannabis material also 
leads to decarboxylation. 
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caught at school, to avoid smelling like cannabis and to 
reduce the respiratory harms associated with smoking. 
Interestingly, some young women said that edibles could be 
a way to avoid publicly presenting themselves as “cannabis 
users.” Both those who used edibles and those who did 
not reported being aware of the potentially negative 
consequences related to edible use. This awareness 
included hearing (perhaps inaccurately) of individuals 
who died from edibles and several youth reported being 
concerned about the high produced by edibles. Females 
who did not use edibles appeared to be more concerned 
than males about these cannabis products and compared 
them to drinks that could be spiked with drugs. By contrast, 
some young men said that “if you can’t handle edibles you 
shouldn’t be using them” (Friese, Slater, Annechino, & 
Battle, 2016). These findings identify attitudes and beliefs 
among young men and women that might be useful in 
prevention and harm reduction messaging. 
Health and Safety Risks
Over-intoxication (or “unexpected high”) as a result of 
over-consumption is arguably the main health risk that 
accompanies edible cannabis products (Allen et al., 2017). 
Since it can take up to four hours for effects to peak, 
people new to cannabis can grow impatient or think that 
the product is ineffective and consume another portion. 
Some individuals might simply not know how much THC 
to consume in an edible cannabis product in the first place, 
resulting in them ingesting a larger amount of THC than 
they can handle. For instance, in March 2014, a young man 
living in Colorado ate a single portion (10 mg of THC) of a 
cookie that contained 65 mg of THC in total. Approximately 
30–60 minutes later, not feeling any effects, he consumed 
the remainder of the cookie. During the next two hours, he 
reportedly exhibited erratic speech and hostile behaviours. 
Approximately three and a half hours after initial ingestion 
and two and a half hours after consuming the remainder of 
the cookie, he jumped off a fourth floor balcony and died 
from trauma (Hancock-Allen, Barker, VanDyke, & Holmes, 
2015). This event led Colorado authorities to change the 
regulations around the labelling and packaging of cannabis 
products, and highlighted the importance of education. To 
minimize the risk, Health Canada has limited the amount 
of THC to 10 mg per package in total, regardless of the 
number of units of edible cannabis in a package, and has 
enforced strict regulations around packaging and labelling.
Over-consumption can lead to the development of psychosis 
(Favrat et al., 2005; Hudak, Severn, & Nordstrom, 2015) and 
can result in serious injury or death. For some individuals, 
over-consumption might also result in cardiovascular events 
(Monte et al., 2019) and stroke (Atchaneeyasakul, Torres, 
& Malik, 2017), although the relative risk of these events 
is currently not known. Public education on the distinct 
pharmacological properties of edible cannabis, including 
dosing, and the delayed onset and longer duration of effects 
can help reduce the risk of over-consumption and over-
intoxication or cannabis poisoning. 
Cannabis in most forms and through most methods of use 
impairs the cognitive and psychomotor abilities needed 
to operate a motor vehicle. Such impairment includes the 
use of edible cannabis. Unlike cannabis products that are 
inhaled, however, the onset and the duration of intoxication 
and impairment after ingesting cannabis is significantly 
delayed (30 minutes to two hours) and persists for up to 
12 hours. It is difficult to predict when the psychoactive 
effects will emerge and when they will subside. This difficulty 
makes it hard to determine when it will be safe for an individual 
to drive a motor vehicle. There are currently no evidence-
based recommendations as to when, after consuming 
edible cannabis, it is safe to drive. More scientific research is 
needed, but in the meantime, as some residual effects (e.g., 
drowsiness) can persist for up to 24 hours, driving during 
this timeframe should be avoided. For more information on 
cannabis and driving, see Clearing the Smoke on Cannabis: 
Cannabis Use and Driving — An Update.
Legalization of edible cannabis products introduces the risk 
of unintentional ingestion, especially by children (Berger, 
2014; Potera, 2015). As an example, Colorado Regional 
Poison Control observed a significant increase in pediatric 
cannabis ingestion cases over the two years following 
cannabis legalization in the state (Wang, Roosevelt, & Heard, 
2016). Children who ingest cannabis vary in the symptoms 
they present, with cardiovascular and respiratory difficulties 
being some of the more severe symptoms (Richards et al., 
2017; Vo et al., 2018). Education around proper storage 
and disposal of cannabis products can reduce the risk of 
unintentional ingestion. 
Food-borne disease is an underappreciated health risk 
associated with edible cannabis. In Europe and the United 
States, the cannabis industry has experienced a number 
of outbreaks and product recalls linked to food-borne 
pathogens, moulds, unsanitary conditions, temperature 
abuse and the presence of pesticides in edible cannabis 
products (Diplock, Leatherdale, & Majowicz, 2017). The 
probability of these risks in Canada, especially within the 
regulated cannabis market, is likely low. However, the same 
cannot be said for edible cannabis products that have been 
produced and sold by illegal and unregulated sources. This 
concern extends to homemade cannabis edible products, 
especially for people who may not be experienced with 
proper food handling and who are selling4 or sharing their 
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4 In Canada, it is illegal to sell any form of cannabis product without the appropriate licence.
“baked goods.” Moreover, homemade cannabis products 
also increase the risk of over-intoxication because the 
individual is unable to predict how much THC they are 
actually consuming. For example, even if the individual knows 
exactly how much THC was in the cannabis extract that 
was used in the brownie recipe and did their best to evenly 
distribute the extract across the entire brownie, without the 
proper lab equipment it is impossible to tell how much THC is 
in one square of brownie versus another square. Purchasing 
regulated products from a licensed retailer is an important 
way for consumers to ensure consistent distribution of THC 
and therefore a more predictable “high.” 
Over-intoxication, unintended ingestion, impaired driving 
and food safety are the immediate health and safety 
concerns that accompany edible cannabis products. 
By contrast, little is known about the long-term health 
consequences of regular use of edible cannabis. Most 
of the risks associated with frequently inhaling THC-
containing products, such as increased risk of psychosis, 
likely apply to ingesting THC products. The unique harms 
associated with edible cannabis, however, might be difficult 
to identify given that individuals who regularly use cannabis 
typically use a variety of other cannabis products, including 
those that are inhaled and ingested. It might, therefore, 
be useful to measure an individual’s “total cannabis (or 
cannabinoid) exposure,” across multiple cannabis products 
and methods, when predicting health outcomes. 
Cannabis Topicals
Cannabis topicals are cannabinoid-infused oils, creams 
and lotions intended for application directly to the skin, hair 
or nails. 
Prevalence and Reasons for Use 
The 2019 Canadian Cannabis Survey indicated that 17% 
of Canadians used topical ointments for medical purposes, 
which did not change from 2018. Topical ointments are 
more common used by Canadian women (11%) than 
men (6%) (Health Canada, 2018). CBD appears to be a 
popular cannabinoid in illicit topical cannabis products, 
largely because this cannabinoid is believed to have anti-
inflammatory and anti-oxidant properties (Milando & 
Friedman, 2019). There is some early research supporting 
the use of topical CBD agents for localized pain and for 
some skin conditions, including psoriasis dermatitis and 
lupus (Dhadwal & Kirchhof, 2018; Maida & Corban, 2017; 
Palmieri, Laurino, & Vadalà, 2019; Sheriff, Lin, Dubin, & 
Khorasani, 2019; Wilkinson & Williamson, 2007). In fact, 
dermatologists are interested in authorizing the use of 
cannabinoids and patients are speaking about cannabinoids 
with their dermatologists (Robinson, Murphy, & Friedman, 
2018). However, few clinical trials have assessed the 
efficacy of topical cannabis products, and the health 
impacts associated with regular and long-term use of these 
products are not known.
Cannabis topicals are also used for a variety of cosmetic 
purposes, including general skincare and haircare, as 
massage oils and for sexual enhancement (e.g., condoms 
comprising cannabis-derived compositions). These appear 
to be fast growing markets in the United States, but it is 
uncertain what these products will ultimately look like in 
Canada. It is worth mentioning, however, that several large 
cosmetic companies have taken advantage of the “cannabis 
hype” following its legalization and released a variety of 
products containing cannabis sativa seed oil. Cannabis 
sativa seed oil is derived from the seeds of the hemp plant, 
which contain no THC and negligible levels of CBD, but is 
marketed as having other ingredients that are good for the 
skin and hair. 
Health and Safety Risks
Since there has been little research on cannabis topicals, 
the health and safety risks associated with the use of these 
products is largely unknown. It appears that applying these 
products to the skin does not elicit psychoactive effects, 
partly because of the low levels of cannabinoids in these 
products and the difficulty of THC penetrating the skin 
barrier. As previously mentioned, permeability enhancers can 
facilitate the transport of cannabinoids into the bloodstream. 
Although unlikely, it is also possible that the application of 
topicals with high levels of THC over large areas of broken 
or damaged skin could deliver amounts of this cannabinoid 
significant enough to produce psychoactive effects. 
Cannabis topicals might also produce allergic reactions, 
including itchiness, swelling and hives, in some individuals 
(Decuyper et al., 2018; Dhadwal & Kirchhof, 2018), and 
there are concerns that topical creams, especially those in 
the unregulated market, could have traces of pesticides, 
fungus or contaminants. 
Pharmacokinetics and Pharmacodynamics 
of Cannabis and Cannabinoids
Pharmacokinetics refers to the way a drug is absorbed, 
distributed, metabolized and eliminated from the body. 
Pharmacodynamics refers to the effects a drug has 
on the brain and body, including the psychoactive — 
intoxicating and impairing — effects associated with 
cannabis. The absorption and metabolism of cannabinoids 
by the body varies by method of administration and this, 
in turn, influences the onset and duration of psychoactive 
effects (Grotenhermen, 2003; Huestis, 2007). 
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Smoking and Vaping
As of the publication date of this document, no published 
scientific studies have examined the pharmacokinetics or 
pharmacodynamics of vaping cannabis extracts. It is likely 
that the time course of psychoactive effects is comparable to 
that of smoked or vaped dried cannabis, and the magnitude 
of psychoactive effects is proportional to the amount of THC 
in the cannabis product. Accordingly, the pharmacokinetics 
and pharmacodynamics of smoked and vaped dried 
cannabis might provide insight into how inhaling extracts 
and concentrates affect the mind and body.
THC is detectible in an individual’s blood during and 
immediately following the smoking of dried cannabis, 
followed soon after by the presence of THC metabolites, 
including 11-OH-THC and THCCOOH (Grotenhermen, 
2003; Huestis, 2007). 11-OH-THC is the psychoactive 
metabolite of THC, whereas THCCOOH seems to have 
no psychoactive properties. Blood concentrations of THC 
peak within 10 minutes from the onset of smoking and 
sharply decrease afterwards, returning to baseline within 
one to four hours (Newmeyer et al., 2016; Spindle et al., 
2018). The concentrations and duration of blood THC 
varies considerably across individuals and this is partly 
related to an individual’s past exposure to cannabis. For 
example, individuals who used cannabis occasionally had 
THC detectible in their blood for 12 minutes to 44 hours after 
inhalation, whereas THC was detectible among individuals 
who frequently used cannabis for more than 72 hours after 
use (Newmeyer et al., 2016). THC is lipophilic (combines with 
or dissolves in lipids or fats) and can be stored in fat tissue 
(Huestis, 2007). This means that regular and heavy cannabis 
use can result in detectible levels of THC and its metabolites 
as much as 30 days after an individual has abstained 
(Bergamaschi et al., 2013). The time course of blood CBD 
levels following inhalation of cannabis smoke appears to 
parallel that of THC (Millar, Stone, Yates, & O’Sullivan, 2018). 
Self-reported drug effects typically emerge within 
10 minutes of inhalation, peak within the first hour and return 
to baseline in about three to four hours (Spindle et al., 2018; 
2019). Importantly, while THC concentrations of five ng/ml 
are related to noticeable intoxication or impairment, levels 
of THC or metabolites do not consistently predict cognitive 
and behavioural outcomes (Spindle et al., 2018; 2019). 
Moreover, self-reported drug effects as well as cognitive 
and psychomotor impairment often persist for several hours 
after systemic THC concentrations returned to basal levels 
(Spindle et al., 2018; 2019). These findings have important 
health and safety implications in the workplace and with 
respect to impaired driving. 
Blood THC concentrations, levels of intoxication and 
impairment are to some extent proportional to the dose of 
THC inhaled (Newmeyer et al., 2016; Spindle et al., 2019). 
Bioavailability5 of THC following inhalation of dried cannabis 
is about 25% to 30%, which is greater than that of ingested 
cannabis (Ashton, 2001; Grotenhermen, 2003). There is, 
however, considerable variation across individuals, which 
have been noted to range from 2% to 56% (Huestis, 
2007). Individual differences in smoking behaviours, 
including depth of inhalation, puff duration and length of 
breath holding, partly influence the bioavailability of THC 
(Grotenhermen, 2003; Huestis, 2007). Sex differences, 
including differences in body mass, can also influence the 
pharmacokinetics of THC. In a recent study, it was shown 
that females exhibited higher levels of blood THC and 
metabolites following equivalent doses of inhaled cannabis 
relative to their male counterparts (Spindle et al., 2019). 
Similar to these findings, it was recently shown that females 
experienced the same acute effects of smoked cannabis 
as males at a lower observed dose (Matheson et al., 2019). 
These findings highlight the need for more research on sex 
differences in the pharmacology of THC, especially when 
it is consumed by routes in which titrating to the desired 
effect is more difficult (e.g., cannabis edibles) (Matheson 
et al., 2019). The average bioavailability of inhaled CBD, 
which has been reported to be 31%, is similar to that of 
THC (Millar et al., 2018). 
Vaping dried cannabis has been shown to have a 
comparable pharmacokinetic profile to that of smoking 
dried cannabis (Newmeyer et al., 2016; Newmeyer, 
Swortwood, Abulseoud, & Huestis, 2017). A recent study, 
however, reported greater blood concentrations of THC 
as well as greater subjective drug effects following vaping 
relative to an equal dose of smoked cannabis (Spindle et 
al., 2018). Indeed, during the smoking of dried cannabis, 
a significant amount of THC is lost to combustion and to 
side stream smoke (Grotenhermen, 2003), whereas these 
are minimized through the use of a vaporizer (Spindle et al., 
2019). For these reasons, vaping might be a more effective 
and efficient method of cannabinoid delivery to the lungs 
and, ultimately, the bloodstream and the brain. Due to 
the greater efficacy of vaping, a lower THC product can 
be used to obtain a similar effect to that of comparatively 
higher THC dried cannabis. 
As mentioned, there have not been any studies of the 
pharmacokinetics and pharmacodynamics of vaporized 
cannabis extracts. However, findings about the vaping 
of dried cannabis might be relevant to cannabis extracts 
and concentrates, given that many of these products 
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5 Bioavailability in this context refers to the percentage of THC in the original cannabis product that ultimately makes it into blood circulation.  
The bioavailability of THC does not represent how much THC makes it to the brain. The percentage of THC that reaches the brain can be much 
lower (< 1%) (McGilveray, 2005).  
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are consumed through vaping methods (e.g., dabbing). 
In this respect, vaping and dabbing of cannabis extracts 
might produce greater psychoactive effects relative to an 
equivalent THC dose of smoked dried cannabis. 
Ingestion 
The absorption of THC and CBD after ingesting a cannabis 
product such as a capsule is considerably slower and 
less predictable than that of inhaled cannabis. The 
unpredictability is because ingested cannabis, including 
the cannabinoids present, are degraded by the acid in 
the stomach and in the gut, and they undergo extensive 
first-pass metabolism by the liver (Grotenhermen, 2003; 
Huestis, 2007). Blood plasma THC concentrations peak 
about one to three hours after ingestion, although for 
some individuals the peak can occur four to six hours 
after consumption (Newmeyer et al., 2016; Vandrey et al., 
2017), and some individuals might display more than one 
blood plasma peak (Huestis, 2007). The bioavailability is 
much lower (~6%) following ingestion and is more variable 
across individuals (4%–20%) relative to inhalation (Ashton, 
2001; Grotenhermen, 2003; Huestis, 2007). However, 
while bioavailability of THC is low, a greater amount of THC 
is converted to the 11 OH THC metabolite when ingested 
(Newmeyer et al., 2016). 
In line with the time course of blood cannabinoids, the onset 
of psychoactive effects has been shown to occur 30 to 
60 minutes after ingestion, to peak at one and a half to 
three hours, and to last six to eight hours (Vandrey et 
al., 2017), although the effects can last longer for some 
individuals. When an edible cannabis product such as a 
brownie is ingested, blood levels of THC, 11-OH-THC 
and THCCOOH were shown to be moderately-to-highly 
correlated with the intensity of intoxication (i.e., subjective 
drug effects) and, to a lesser extent, cognitive impairment 
(Vandrey et al., 2017). It should, however, be underscored 
that blood levels of THC and other cannabinoids are 
significantly lower following ingestion relative to inhalation, 
and blood concentrations of three ng/ml can be associated 
with significant intoxication and impairment. Thus, absolute 
values of blood plasma THC, 11-OH-THC and THCCOOH 
following ingestion of a cannabis product might not be 
strongly predictive of the magnitude of intoxication and 
impairment, especially among individuals who are new to 
cannabis (Vandrey et al., 2017). 
Sublingual and Buccal Administration 
Sublingual administration is when a drug is applied and held 
under the tongue, whereas buccal administration is when 
a drug is applied inside the cheek. The pharmacokinetics 
and pharmacodynamics of these routes of administration 
of cannabis products have not been extensively studied. 
Since sublingual and buccal administration bypass the gut 
and first-pass metabolism by the liver, they are believed 
to be more efficient drug delivery methods than ingestion. 
Based on this reasoning, tinctures, which are administered 
sublingually, are thought to produce a quicker onset of 
psychoactive or therapeutic effects relative to an ingested 
cannabis product. 
The available evidence is mixed and more complex. In an 
earlier study, the presence of THC, 11 OH THC and CBD were 
detectible in blood plasma within 30 minutes, regardless of 
method of administration. However, peak concentrations of 
THC and 11-OH-THC were highest following ingestion of a 
10 mg THC and 10 mg CBD dose relative to an identical 
dose that was administered sublingually or buccally. 
Additionally, peak THC concentrations were reached 
the fastest following the ingestion method (63 minutes), 
followed by sublingual (98 minutes), then buccal (~170 
minutes) administration (Guy & Robson, 2004b). A more 
recent study did not find significant differences in peak 
concentrations and in time to peak concentration, which 
occurred two to four hours after administration, following an 
oral dose of synthetic THC and a similar dose of Sativex®.6 
However, slightly greater bioavailability was noted after 
Sativex administration, whereas higher concentrations 
of 11-OH-THC were detected after ingestion of oral THC 
capsules (Karschner et al., 2011). 
Studies examining the pharmacokinetics of sublingual and 
buccal administration commonly found a considerable 
degree of variability across individuals (Guy & Robson, 
2004a, 2004b; Karschner et al., 2011). The variability is 
partly related to individuals swallowing some of the cannabis 
product. It has not been possible to distinguish between 
blood plasma cannabinoids attributable to sublingual or 
buccal absorption and those absorbed through ingestion 
(Karschner et al., 2011). Further, previous cannabis 
exposure seems also to play a role in this variability, where 
individuals who use cannabis more frequently display a more 
rapid increase in blood THC following dose administration, 
an effect suggested to be related to the saturation of fat 
stores with THC (Karschner et al., 2011). 
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been approved in Canada as an adjunctive treatment for symptom relief of spasticity in adult individuals with multiple sclerosis (Bayer, 2019).
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The pharmacodynamics, including the onset, duration and 
magnitude of psychoactive effects, have not been well 
characterized following sublingual and buccal administration 
of a cannabis extract. For individuals who reported 
intoxication following the use of Sativex, they generally did 
so between 30 and 150 minutes after dose administration, 
but there was large variability among individuals (Guy & 
Robson, 2004a, 2004b). More research using larger sample 
sizes is needed to determine how different formulations (e.g., 
alcohol- versus oil-based) and cannabinoid profiles (e.g., 
THC:CBD ratios) influence the pharmacological properties 
of cannabis extracts when taken sublingually and buccally.
Topical and Transdermal Application 
Since cannabinoids are highly hydrophobic — that is, they 
repel water — it is difficult to transport these molecules 
across the aqueous layer of the skin (Huestis, 2007). 
This fact is partly why cannabis topicals are thought to 
have no effect on the central nervous system and not be 
able to cause intoxication and impairment. However, this 
supposition has not been extensively tested in humans and 
over the range of possible cannabis topical formulations. 
Indeed, it appears that certain cannabinoids are more skin-
permeable than others (e.g., Δ8-tetrahydrocannabinol), 
and that the use of transdermal patches with “permeation 
enhancers” can facilitate absorption through the skin (Bruni 
et al., 2018). Preclinical studies have shown that topical 
cannabinoid application, with and without enhancers, can 
result in notable blood concentrations of cannabinoids 
that can persist for long periods of time (e.g., more than 
48 hours) (Health Canada, 2018). Once again, however, 
there have been no clinical studies examining the presence 
of systemic cannabinoid levels and the potential for 
psychoactive effects following the use of topical and 
transdermal cannabis products. 
Conclusions and Implications
The recent legalization of edible cannabis products, cannabis 
extracts and cannabis topicals introduces Canadians to a 
wide array of cannabis products. As emphasized throughout 
this report, these new classes of cannabis products carry 
with them health and safety risks that are not part of using 
dried cannabis, and the health impacts associated with 
long-term use of these products are not known. The new 
products and methods of administration can facilitate 
cannabis use in locations that require discretion, and the 
increased availability of vaporizers and edible cannabis 
products could increase the risk of cannabis-related 
problems in settings such as the classroom or the highway. 
Public education, prompt dissemination of novel research 
findings and careful monitoring of policies around these 
products are central to mitigating the harms. CCSA has 
developed a number of resources that can be found at 
ccsa.ca/research-cannabis under the New Cannabis 
Products tab, including a two-page primer on the 
new cannabis products. For information on cannabis 
policy and regulations across provinces and territories, visit 
ccsa.ca/policy-and-regulations-cannabis.
The term cannabis extracts describes a vast number of 
products that differ considerably in their appearance, taste, 
smell and, most importantly, their THC:CBD ratio. While 
we do not understand the full scope of the health effects 
of cannabis extracts, it is reasonable to suspect that the 
risks are proportional to the concentrations of THC in a 
product.7 Cannabis concentrates carry with them a higher 
risk of over-intoxication than dried cannabis and less potent 
cannabis products. Regular use of concentrates has 
been associated with cannabis dependence and mental 
health disorders, and the risk of developing a psychotic 
disorder seems to be related to levels of THC. While edible 
cannabis has received the most media attention around 
the legalization of new classes of cannabis, it is the high-
potency concentrates that arguably carry the most risk of 
harm. Public education on how to read and understand 
package labelling should be a priority as these products 
come on the market. At the same time, research on the 
pharmacokinetics and pharmacodynamics of the range of 
cannabis extracts such as shatter and the new methods of 
use such as dabbing is needed to inform public education 
efforts. CCSA has developed 7 Things You Need to Know 
about Cannabis Extracts, a list of tips to lower the risks 
associated with cannabis extracts and concentrates.
The main concern associated with edible cannabis products 
is over-consumption causing over-intoxication, especially 
among those new to cannabis. In most cases, this happens 
when someone is unaware that the onset of psychoactive 
effects is delayed up to four hours after ingesting cannabis. 
The delay can lead the individual to consume more 
cannabis and eventually become over-intoxicated. Even 
being aware of the delay in onset and the longer lasting 
effects, it can be difficult for an individual new to edible 
cannabis to determine what dose of THC to start with. 
The legal THC limit for a unit of edible cannabis product is 
10 mg. For some, this amount of THC might produce a mild 
to moderate high, whereas for others 10 mg of THC could 
cause severe intoxication and impairment. While variability 
in the psychoactive effects and blood cannabinoid levels 
that result from ingesting edible cannabis products has 
often been reported, the causes of this variability are not 
well understood and research into them is ongoing. In the 
meantime, people are recommended to “start low and go 
slow,” consuming no more than 2.5 mg of THC at one time 
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in a food or drink product. For CCSA resources on edible 
cannabis, see Edible Cannabis: Always Read the Label, 
7 Things You Need to Know about Edible Cannabis and 
Cannabis: Inhaling vs Ingesting.
There is a limited amount of scientific evidence on cannabis 
topicals. There have not been any studies looking at the 
pharmacokinetics and pharmacodynamics on topical 
cannabis products in humans or their impact on health 
following long-term use. Cannabis topicals do not seem 
to produce intoxicating or impairing effects, partly because 
cannabinoids do not penetrate the skin well and so do not 
reach the bloodstream. This feature of topicals has not been 
tested across the range of possible topical formulations and 
methods of delivery (e.g., transdermal patches). Preclinical 
studies show that topical application of cannabinoids 
resulted in measureable blood concentrations that were 
present for long periods (Paudel, Hammell, Agu, Valiveti, & 
Stinchcomb, 2010; Valiveti, Hammell, Earles, & Stinchcomb, 
2004). These findings from animal research might have 
implications for driving and in workplaces that conduct drug 
testing. Although cannabis topicals are being marketed for 
several medical purposes (e.g., arthritis and skin diseases), 
their effectiveness has not been well established. 
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The focus of this report has been on the potential harms or 
health impacts of the new classes of cannabis. This focus 
reflects the available but limited evidence on edible cannabis 
products, cannabis extracts and cannabis topicals. That 
this report has not touched on the medical or therapeutic 
role of the new classes of cannabis products and methods 
of use is not to say that they have none. In fact, certain 
methods of cannabinoid delivery such as ingestion and 
transdermal application might provide therapeutic value, 
while minimizing the negative health outcomes associated 
with other methods of use such as the harms to the 
respiratory system from smoking cannabis. Ingested and 
topical cannabis products provide longer lasting therapeutic 
effects, whereas inhaled products provide more immediate 
ones. Clearing the Smoke of Cannabis: Medical Use of 
Cannabis and Cannabinoids — An Update offers a more 
comprehensive discussion on these topics. Research 
and monitoring of edible cannabis products, cannabis 
extracts and cannabis topicals as well as sustained public 
education about them should continue. These initiatives 
could mitigate the health and safety concerns associated 
with the use of these new classes of cannabis products. 
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